



DISCOVERY & DEVELOPMENT OF SELECTIVE M₃ ANTAGONISTS FOR CLINICAL USE

V.A. Alabaster

Department of Discovery Biology
Pfizer Central Research, Sandwich, Kent, CT13 9NJ, U.K.

Summary

The treatment of airway obstructive disease may be improved by antimuscarinic agents which selectively block M₁ and M₃ receptors but do not inhibit prejunctional cholinergic autoreceptors which limit release of acetylcholine. Revatropate is a novel antimuscarinic agent which shows some 50-fold selectivity for M₁ and M₃ receptors in guinea pig trachea and rabbit vas deferens over the M₂ subtype in atria. This selectivity profile was seen *in vivo* in anaesthetised guinea pigs and conscious dogs where bronchodilator activity was produced in the absence of any effect on heart rate. Revatropate, in contrast to the non-selective agent ipratropium, did not potentiate bronchoconstrictor responses induced by vagal nerve stimulation, indicating that inhibitory autoreceptors were still functional. Early clinical studies in COAD patients showed that inhaled revatropate was an effective bronchodilator which was well tolerated. Darifenacin differs from revatropate by showing selectivity for M₃ receptors relative to both M₂ and M₁ subtypes. [³H] darifenacin had 5-fold higher affinity for the human m₃ relative to m₁ receptors while there was significantly reduced binding to m₂, m₄ and m₅ receptors. The degree of selectivity in functional tissue preparations was even greater, with darifenacin showing 100-fold selectivity for the ileum M₃ receptors over M₂ receptors in atria and 30-fold over M₁ receptors in rabbit vas deferens. Darifenacin was able to differentiate between M₃ receptors in different tissues; although darifenacin was equipotent with atropine in the ileum and bladder, it was some 10-fold and 6-fold less potent at inhibiting muscarinic responses in the trachea and submandibular salivary gland respectively, relative to atropine. Studies in anaesthetised dogs confirmed this selectivity profile. Thus darifenacin inhibited responses of the gut and bladder to cholinergic stimulation without affecting heart rate. Salivary gland responses were inhibited at doses some 6-10 fold higher than those required to inhibit gut and bladder responses. Clinical studies are ongoing in urge incontinence and functional bowel disease which may confirm this selectivity profile.

Key Words: muscarinic receptor subtypes, M₃ antagonists, preclinical pharmacology

The *Datura* genus of plants which contain atropine and related anticholinergic alkaloids, have been used by man for several thousand years for a variety of medical and other purposes. Thus for example, inhalation of smoke from the herb *Datura stramonium* was recommended for the treatment of asthma in the seventeenth century (1). However, drying of secretions, tachycardia, urinary retention, blurred vision and central nervous system effects were all recognised complications associated with the use of atropine containing compounds and preparations. Muscarinic antagonists are still widely used, for example oxybutynin in urinary urge incontinence and dicyclomine in irritable bowel syndrome, but the clinical utility of these non-selective agents is still limited by adverse side effects.

In 1976, Barlow's studies of the relative activities of a series of muscarinic antagonists in the guinea pig ileum and the rabbit atrium indicated that responses in these two tissues were mediated by different receptors (2). Further work clearly established the heterogeneity of muscarinic receptors and they have been classified using pharmacological techniques into M₁, M₂, M₃ and M₄ subtypes, and on genomic cloning into m1, m2, m3, m4 and m5 subtypes (3). Thus the possibility of designing sub-type selective agents to achieve efficacy with reduced side-effects was a feasible and exciting possibility. Muscarinic M₃ receptors are located predominantly on smooth muscle and salivary glands, and it was considered that agents selective for this sub-class of receptors could have therapeutic utility in the treatment of incontinence, disorders of gastro-intestinal motility and as bronchodilators in respiratory disease. We therefore initiated projects at Pfizer to identify M₃ selective antagonists and this paper describes the profile of 2 such agents, revatropate (UK-112,166) and darifenacin (UK-88,525) (Fig. 1).




Fig. 1

Structural formulae of novel M₃ antagonists.**Revatropate: - a drug for treatment of COAD**

Activation of cholinergic nerves is the major bronchoconstrictor neural mechanism in animal and human airways and there is evidence that this mechanism may be overactive in

muscarinic receptors M₁, M₂, and M₃ have been identified in human airways and their location and possible physiological function have been extensively reviewed (5). Stimulation of the vagus nerve releases acetylcholine (ACh) which activates muscarinic receptors on airway smooth muscle (M₃) and submucosal gland (M₃) to induce bronchoconstriction and mucus secretion respectively. M₁-receptors facilitate neurotransmission through parasympathetic ganglia and possibly enhance cholinergic reflexes. Additionally, there are also autoreceptors on cholinergic nerve terminals innervating bronchial and tracheal smooth muscle which inhibit ACh output when activated (6, 7) which have been characterised as the M₂ muscarinic subtype (5, 8). (In the guinea pig, there is some evidence that these autoreceptors may be more M₄-like rather than M₂ (9)). Thus a rational approach to producing an improved agent to treat airways obstruction was to identify a compound which selectively inhibited M₃ and M₁ muscarinic receptors, but unlike non-selective agents such as ipratropium, did not interfere with the neurotransmitter negative feedback loop by blockade of M₂ (or M₄)-receptors.

The *in vitro* profile of revatropate is shown in Table I. Revatropate showed potent antagonism of M₁ and M₃ receptors with some 50-fold selectivity over the M₂ subtype. This was in contrast to ipratropium which was also potent, but non-selective (10).

TABLE I
In vitro profile of revatropate and ipratropium.

TISSUE/SUBTYPE	REVATROPATE			IPRATROPIUM		
	pA ₂ (95% conf. limits)	slope	n	pA ₂ (95% conf. limits)	slope	n
Rabbit vas deferens M ₁	9.26 (8.93-9.93)	1.06	11	9.44 (9.16-9.86)	1.11	14
Guinea pig atria M ₂	7.25 (7.12-7.39)	1.19	16	9.15 (8.91-9.45)	1.21	4
Guinea pig trachea M ₃	8.92 (8.67-9.24)	0.97	17	9.45 (9.24-9.73)	1.38	12

n=number of tissues

This selectivity profile was also seen *in vivo*. Thus in anaesthetised guinea pigs, revatropate antagonised ACh-induced M₃ mediated bronchoconstrictor responses at some 80-fold lower doses than those required to inhibit ACh-induced M₂ mediated bradycardia (10). Ipratropium inhibited both responses over a similar dose range.

The functional involvement of pre-junctional muscarinic receptors on post-ganglionic airway cholinergic nerves that inhibit the release of ACh in lung responses to nerve stimulation has been demonstrated in animal experiments (5, 8, 11). For example, bronchoconstrictor responses to vagal nerve stimulation were potentiated by the M₂/M₄-selective antagonist methoctramine, indicating inhibition of the inhibitory feedback control on ACh release. Similar experiments were carried out in our laboratories in anaesthetised guinea pigs and cats with revatropate and ipratropium, comparing their effect on bronchoconstriction induced by vagal stimulation with responses to injected ACh (12). Ipratropium potently inhibited i.v. ACh-induced bronchoconstriction in both species (ID₅₀ 1.45 µg/kg in guinea pig, 0.08 µg/kg in cat). Significantly higher doses were required to inhibit responses to vagal nerve

stimulation (ID₅₀>10µg/kg in guinea pig, 2.1µg/kg in cat). Additionally, low doses of ipratropium potentiated the bronchoconstriction responses to vagal-nerve stimulation by up to 150%. (See Fig 2). Revatropate also potently inhibited the bronchoconstrictor response to i.v. ACh (ID₅₀ 0.94µg/kg in guinea pig and 0.52 µg/kg in cat). However, in contrast to ipratropium, responses to vagal stimulation were similarly inhibited over the same dose range (ID₅₀ 1.7µg/kg in guinea pig, 1.03µg/kg in cat). Potentiation of the vagal response was not observed at any dose. The data from guinea pigs are shown in Fig 2.




Fig. 2

Selectivity of revatropate for post-junctional M₃ receptors over pre-junctional autoreceptors - comparison with ipratropium in anaesthetised guinea pigs.

The bronchodilator activity and lung selectivity of revatropate was confirmed in conscious dogs where revatropate, given orally and by metered-dose inhaler, antagonised nebulised methacholine-induced bronchospasm without affecting heart rate (13).

The role of the autoreceptor on pre-junctional cholinergic nerve terminals in the airways in man is unknown, but indirect clinical pharmacology studies indicate their presence in non-asthmatics but absence in asthmatic subjects (14). It is possible, that while neuronal M₂ receptors exert an important inhibitory control on the parasympathetic nerves supplying the airway smooth muscle in normal circumstances, the situation may be different in the disease state. Thus measurements of vagal-induced bronchoconstriction responses in guinea pig indicated that prejunctional autoreceptors are dysfunctional after exposure to viral airway infections, ozone or antigen inhalation (15). Inflammatory mediators and/or eosinophil degranulation products were implicated in the loss of M₂ function in these studies.

The first clinical study evaluating the effect of revatropate in COAD patients was very encouraging. Forty two COAD patients were studied in a double-blind 3 treatment cross-over study, designed to compare the response to 320µg revatropate, 80µg ipratropium bromide and

placebo given via Meter Dose Inhaler (16). The mean increase from pre-dose FEV₁ to peak-post dose FEV₁ was 0.34L (+27%) on revatropate, 0.36L (+29%) on ipratropium bromide and 0.15L (+12%) on placebo. Revatropate was well tolerated and no side effects were reported. Further studies are required to explore the dose-response relationships, and these may reveal advantages over non-selective agents.

Darifenacin

The functional smooth muscle responses induced by cholinergic nerve stimulation to the bladder and gut are mediated via M₃ receptor activation (3). Darifenacin differs from revatropate by showing selectivity for the M₃ subtype relative to all other muscarinic receptor subtypes and hence is anticipated to have an advantage over non-selective anti-muscarinic agents in the treatment of urge incontinence and functional bowel disease.

The binding of [³H]-darifenacin to the five cloned human muscarinic receptors (m1 - m5) expressed in CHO cells was compared (17). [³H]-darifenacin was found to bind with 5-fold higher affinity to m3 (K_D, 0.33nM) over m1 (K_D, 1.6nM) receptors. There was no specific binding to m2 receptors and specific binding to m4 and m5 receptors was insufficient to determine a K_D. Competition studies in cells expressing m3 and m1 receptors using a range of muscarinic antagonists showed that darifenacin represents the first selective m3 ligand. A greater degree of selectivity for the M₃ receptor subtype was observed in functional *in vitro* studies. The pA₂ values for darifenacin and atropine versus muscarinic activation in a variety of tissue preparations are shown in Table II. Atropine was essentially non-selective while darifenacin showed 100-fold selectivity for ileum M₃ receptors over M₂ receptors in atria and 30-fold over M₁ receptors in rabbit vas deferens (18, 19).

TABLE II
In vitro profile of darifenacin and atropine.

TISSUE/SUBTYPE	DARIFENACIN			ATROPINE		
	pA ₂ ± sem	slope	n	pA ₂ ± sem	slope	n
Guinea pig ileum M ₃	9.44 ± 0.07	1.16	6	9.4 ± 0.07	0.96	6
Guinea pig trachea M ₃	8.70 ± 0.09	1.08	6	9.20 ± 0.1	1.18	6
Guinea pig bladder M ₃	8.66 ± 0.14	1.01	4	9.01 ± 0.09	0.86	4
Guinea pig atria M ₂	7.48 ± 0.13	0.84	6	8.72 ± 0.06	1.13	7
Rabbit vas deferens M ₁	7.90 ± 0.08	0.94	6	9.58 ± 0.09	0.9	7
Guinea pig salivary gland M ₃	7.0 ± 0.1 (pIC ₅₀)	-	4	7.87 ± 0.14 (pIC ₅₀)	-	4

Functional responses to cholinergic activation of salivary glands are also mediated by the M₃ muscarinic subtype. However, although darifenacin was equipotent with atropine in the ileum and bladder preparations, darifenacin was some 6-fold less potent at inhibiting carbachol-induced ⁸⁶Rb efflux from the submandibular salivary gland and 10-fold less potent at

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.